Clinical Trials Sponsored by Novartis Pharmaceuticals

Total 21388 results

Teva Branded Pharmaceutical Products R&D, Inc.
Cephalon; ChemGenex Pharmaceuticals

Completed

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Chronic Myeloid Leukemia

United States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
Auspex Pharmaceuticals, Inc.

Completed

Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD)

Tardive Dyskinesia

United States, Poland, Czechia, Slovakia
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

China, Belgium, Thailand, United States, Spain, Canada, Colombia, Italy, Morocco, Brazil, Turkey, Chile, Malaysia, Israel, Portugal, Singapore, Russian Federation, Philippines, Tunisia, Austria, Czechia, Germany, Hungary, India, Poland, R... and more
Teva Pharmaceuticals Europe

Completed

Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease (SPRINT)

Chronic Obstructive Pulmonary Disease | Asthma

Croatia, Denmark, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom
Spanish Breast Cancer Research Group
Novartis Pharmaceuticals; ETOP IBCSG Partners Foundation; Breast International...

Active, not recruiting

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (ALPHABET)

Advanced Breast Cancer

Spain, Netherlands, France, Italy, Austria, Switzerland
National Institute of Allergy and Infectious Diseases...
Novartis Pharmaceuticals; Autoimmunity Centers of Excellence

Completed

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Novartis Pharmaceuticals; The Skip Viragh Foundation

Terminated

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Dana-Farber Cancer Institute; Novartis Pharmaceuticals

Completed

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Malignant Pleural Mesothelioma

United States
Institut fuer anwendungsorientierte Forschung und...
Novartis Pharmaceuticals; University Medical Center Goettingen

Completed

Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. (RABIMO)

Macular Degeneration

Germany
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

Healthy Volunteers

United States
Portola Pharmaceuticals

Withdrawn

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

AITL | Peripheral T-Cell Lymphoma (PTCL NOS) | Nodal Lymphomas of T Follicular Helper (TFH) | Follicular T-cell Lymphoma (FTCL) | ALCL | HSTCL | EATL I,II | MEITL, EATL Type II | Nasal Lymphoma
Portola Pharmaceuticals

Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

United States
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Healthy

Belgium
Ferring Pharmaceuticals
Xanodyne Pharmaceuticals

Completed

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

Menorrhagia

United States
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Squamous Cell Carcinoma of the Oropharynx | HPV16 Positive

Netherlands, United States, United Kingdom, France, Belgium, Czechia, Spain, Italy, Germany, Brazil, Hungary, Mexico, Poland
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Portola Pharmaceuticals

Withdrawn

BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

Venous Thromboses

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Completed

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Seizures | Tuberous Sclerosis Complex

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Pharmacokinetic Evaluation of Testosterone Gel (1%)

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx

United States, Israel, Belgium, Germany, Spain, United Kingdom, Italy, France, Czechia
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Terminated

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Rett Syndrome | RTT

United States, Canada, Italy, Spain, United Kingdom, Australia
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
Nationwide Children's Hospital
Novartis

Not yet recruiting

Study of Ribociclib and Everolimus in HGG and DIPG

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Massachusetts General Hospital
Novartis

Recruiting

MBG453 in Lower Risk MDS

Myelodysplastic Syndromes

United States
University of Miami
Novartis

Recruiting

Brain Changes in Psoriasis After Secukinumab Treatment

Healthy | Psoriasis

United States
University of Pennsylvania
Novartis

Recruiting

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Psoriasis

United States
Haukeland University Hospital
Novartis

Withdrawn

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (DefeHEMY)

Myelodysplastic Syndromes | Hemochromatosis

Norway
Technische Universität Dresden
Novartis

Terminated

A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients (DELTA)

Acute Myeloid Leukemia

Germany
Boston Children's Hospital
Novartis

Completed

Pilot Study for Patients With Poor Response to Deferasirox

Sickle Cell Disease | Thalassemia Major | Transfusion-dependent Hemachromatosis

United States
Mirati Therapeutics Inc.
Novartis

Active, not recruiting

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Metastatic Cancer | Advanced Cancer | Malignant Neoplastic Disease

United States
Medical University Innsbruck
Novartis

Completed

68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

Neuroendocrine Tumors

Austria
ARCAGY/ GINECO GROUP
Novartis

Completed

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer (TAPAZ)

Ovarian Cancer

France
Massachusetts General Hospital
Novartis

Active, not recruiting

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
University of L'Aquila
Novartis

Active, not recruiting

MicroRNA Profile and Erenumab Treatment

Migraine

Italy
Ohio State University
Novartis

Completed

Comparing Everolimus and Sirolimus in Renal Transplant Recipients

Renal Failure

United States
Dermatology Specialists Research
Novartis

Completed

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

Seborrheic Dermatitis

United States
Massachusetts General Hospital
Novartis

Completed

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Malignant Non-small Cell Neoplasm of Lung Stage IV

United States
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)

Asthma
Organon and Co
Novartis

Completed

A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)

Asthma | COPD
PrECOG, LLC.
GlaxoSmithKline; Novartis

Terminated

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission (PrE0901)

Acute Myeloid Leukemia

United States
University Hospital, Akershus
Novartis

Active, not recruiting

Heart Failure in Norway: Clinical Characteristics, Mortality and Health Care Resource Use

Heart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction

Norway
University of Chicago
Novartis

Terminated

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Human Papillomavirus Infection | Recurrent Oropharyngeal Squamous Cell Carcinoma | FGFR Gene Amplification | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | Recurrent Nasopharynx...

United States
University Hospital, Brest
Novartis

Unknown

Neuroendocrine Tumors of Old Patients in the West of France (TANGO)

Neuroendocrine Tumors

France
University Hospital, Bordeaux
Novartis

Completed

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (EVERCMV)

Transplantation Infection | Cytomegalovirus Infection

France
Samsung Medical Center
Novartis

Completed

The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
University of Leipzig
Novartis

Withdrawn

Cutaneous Lupus Erythematosus and Elidel

Lupus Erythematosus, Cutaneous | Lupus Erythematosus, Discoid

Germany

Clinical Trials Sponsored by Novartis Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations